Literature DB >> 3009351

Monoclonal antibodies to genus- and type-specific papillomavirus structural antigens.

Y Nakai, W D Lancaster, L Y Lim, A B Jenson.   

Abstract

Monoclonal antibodies against SDS-disrupted bovine papillomavirus type 1 (BPV1) were obtained from hybridomas prepared by fusing mouse myeloma cell line P3X63Ag8U1 with spleen cells from immunized BALB/c mice. Six hybridoma cell lines were obtained after testing supernatant fluids for positivity by the enzyme-linked immunosorbent assay using the immunogen as antigen and by indirect immunofluorescence (IF) on frozen sections of BPV1-induced bovine fibropapillomas. Monoclonal antibodies (AU1-AU6) from these hybridomas were then tested for reactivity by IF tests on BPV2-induced fibropapillomas and on human plantar warts and vulvar condylomas and by avidin-biotin complex tests on sections of formalin-fixed cervical dysplasias. One monoclonal antibody (AU1) was reactive with all tissues, four (AU3-AU6) were reactive with both BPV1 and BPV2 fibropapillomas, and the remaining antibody (AU2) was only reactive with BPV1-induced fibropapillomas. All monoclonal antibodies reacted with the major capsid protein (mol. wt. 54,000) of BPV1, whereas five (AU1, AU3-AU6) reacted with the major capsid protein of BPV2. These results indicate that papillomavirus genus-specific, cross-reactive, and type-specific antigenic determinants are located on the major capsid protein of BPV1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009351     DOI: 10.1159/000149652

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  11 in total

1.  Human N-myristoyltransferases form stable complexes with lentiviral nef and other viral and cellular substrate proteins.

Authors:  Brian T Hill; Jacek Skowronski
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 2.  Cancer of the cervix: prospects for immunological control.

Authors:  D H Davies; G A McIndoe; B M Chain
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

3.  G2 arrest in Xenopus oocytes depends on phosphorylation of cdc25 by protein kinase A.

Authors:  Brian C Duckworth; Jennifer S Weaver; Joan V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

4.  Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope.

Authors:  S A Jenison; X P Yu; J M Valentine; D A Galloway
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Expression of human papillomavirus types 6b and 16 L1 open reading frames in Escherichia coli: detection of a 56,000-dalton polypeptide containing genus-specific (common) antigens.

Authors:  Y Tomita; H Shirasawa; B Simizu
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

6.  Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses.

Authors:  L Dillner; P Heino; J Moreno-Lopez; J Dillner
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 7.  Human papillomaviruses: are we ready to type?

Authors:  A Roman; K H Fife
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

8.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins.

Authors:  S A Jenison; J M Firzlaff; A Langenberg; D A Galloway
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

10.  Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).

Authors:  Bettina Huber; Christina Schellenbacher; Saeed Shafti-Keramat; Christoph Jindra; Neil Christensen; Reinhard Kirnbauer
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.